atrophy/obesity

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 55 rezilta yo

Screening methods for compounds useful for the treatment of body weight disorders, including obesity

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. INTRODUCTION The present invention relates to the mammalian tubby (tub) genes, including the human tub gene, which are novel genes involved in the control of mammalian body weight, including recombinant DNA molecules, cloned genes or degenerate variants thereof. The present invention further

Compositions for the treatment and diagnosis of body weight disorders, including obesity

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Administration of nicotinamide mononucleotide in the treatment of disease

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

INTRODUCTION Age-related obesity is a health-related problem for which new treatments and methods of ameliorating, mitigating, or reversing are needed. U.S. Pat. No. 8,268,575 to Imai, S., et al. asserts that "Chemical effectors for mammalian NAD biosynthesis can mediate a variety of anti-aging

Administration of nicotinamide mononucleotide in the treatment of disease

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

2-Aminoquinoline compounds

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION Obesity, defined as excess adiposity for a given body size, results from a chronic imbalance between energy intake and energy expenditure. Body mass index (BMI, kg/m.sup.2) is an accepted clinical estimate of being overweight (BMI 25 to 30) and of obesity (BMI>30). A

Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-.alpha. modulators

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and for treating conditions such as cancer, arthritis, inflammatory airway disease, and metabolic disorders. More particularly, the

Melanocortin receptor ligands

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention relates to new melanocortin receptor ligands. These ligands are cyclic peptide analogs that preferably exhibit selectivity for the MC-4 and/or the MC-3 receptors relative to the other melanocortin receptors (in particular the MC-1 receptor). BACKGROUND OF

Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention concerns the preparation and uses of adamantanamines (e.g. memantine, amantadine and rimantadine) and neramexane(s) salts of thiomolybdic acids and thiotungstic acids. Their pharmaceutical compositions incorporate two complementary, bioavailable

Thiazole derivatives

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The subject invention relates to thiazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present

Imidazole derivatives

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The subject invention relates to imidazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present

Imidazole derivatives

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Deuterium-enriched pyridinonecarboxamides and derivatives

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinonecarboxamides and derivatives thereof of formula 1, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

Anti-ACTH antibodies and use thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

SEQUENCE DISCLOSURE The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on May 23, 2017, is named "43257o5404.txt" and is 541,238 bytes in size. FIELD This invention

Anti-ACTH antibodies and use thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

SEQUENCE DISCLOSURE The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on Feb. 20, 2015, is named "43257o5402. txt" and is 541,162 bytes in size. FIELD This

Humanized anti-ACTH antibodies and use thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

SEQUENCE DISCLOSURE The instant application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on Dec. 18, 2014, is named "43257o5600.txt" and is 681,004 bytes in size. FIELD This

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye